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Background: Early onset pancreatic cancer (EOPC), i.e. pancreatic ductal adenocarcinoma (PDAC) occurring in patients
below 50 years of age, is rare and there is limited information regarding risk factors, molecular basis and outcome. This
study aimed to determine the demographic and clinicopathological features and survival figures for EOPC.
Methods: A retrospective analysis of patients treated at the Royal London Hospital for PDAC between September 2004
and September 2015 was performed. Data on demographics, risk factors, presentation, pathological features, treatment
and survival outcome were compared in EOPC and older PDAC patients.
Results: Of 369 PDAC cases identified, 35 (9.5%) were EOPC. Compared to older patients, EOPC patients were more
frequently male (71% vs 54%, p = 0.043) and less commonly of British origin (37% vs 70%, p = 0.002). There
was no significant difference regarding the prevalence of any of the risk factors known to be associated with
older PDAC patients. Fewer EOPC patients presented with resectable disease (23% vs 44%, p = 0.015) and more
received adjuvant chemo/radiotherapy (60% vs 46%, p = 0.008). The overall median survival and stage specific survival
did not differ significantly between the two groups, although a longer survival for localized disease was seen in EOPC
patients (25 months (12.9–37, 95%CI) vs 13 months (10.5–15.5 95%CI) for older PDAC patients).
Conclusions: The EOPC patients had different demographics and were more likely than their older PDAC counterparts
to be male. Typically they presented with more advanced disease, received more aggressive treatment, and had on
overall similar survival outcome.
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Pancreatic ductal adenocarcinoma (PDAC) is the most
common pancreatic malignancy. It is the fourth leading
cause of cancer death with a 7% five-year survival rate in
the United States [1], and is predicted to be the second
cause of cancer-related death by 2030 [2]. The mean age
of PDAC patients at presentation is 71 years [3]; how-
ever, 5–10% of these patients are diagnosed with this
malignancy at a young age, when they are less than
50 years old [4–7]. This important subgroup of PDAC
patients, often referred to as early onset pancreatic can-
cer (EOPC), has been poorly studied, and the cause of* Correspondence: t.c.jurcevic@qmul.ac.uk
1Barts Cancer Institute, Queen Mary University of London, John Vane Science
Centre, Charterhouse Square, London EC1M 6BQ, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zesuch an early presentation of the disease remains un-
known [6, 8–14].
PDAC is considered to be more frequent in individuals
with familial history [15–18] and hereditary genetic syn-
dromes, such as Hereditary Pancreatitis (HP) [19–21],
Lynch syndrome [22] and Peutz-Jeghers syndrome
[23, 24]. Modifiable risk factors include tobacco expos-
ure, alcohol use, chronic pancreatitis, diabetes mellitus,
diet, obesity, previous radiotherapy, as well as certain
types of abdominal surgery and infections [25–33]. Also,
an inverse association between PDAC and atopic diseases
has been identified [34].
In this report, we provide the data of a comprehensive
and systematic study on demographics and known
PDAC risk factors, as well as detailed clinicopathologi-
cal, treatment and outcome figures for EOPC patients.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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on PDAC patients collected over the 11-year period be-
tween September 2004 and September 2015, from one
of the major Hepato-Pancreato-Biliary (HPB) referral
hospital centres in London, UK. We compared these
data to the data collected for the older PDAC patients
from the same centre in order to identify differences and
potentially suggest clues to the biology of the disease.
Methods
Database search and data extraction
We conducted a search of the pathology archives and
patients’ database at the Royal London Hospital for
period between 18/9/2004 to 18/9/2015 in order to iden-
tify patients who were diagnosed with pancreatic ductal
adenocarcinoma. We used the topography search codes
“pancreatic structure” and “pancreas and duodenum”,
and included pancreatic FNAs (fine needle aspirations),
core biopsies and surgical resection specimens with a
pathology diagnosis of pancreatic ductal adenocarcin-
oma or adenocarcinoma with features “compatible with”,
“suggestive of” or “typical of” pancreatic ductal origin.
We excluded all other histologic subtypes and cases of
adenocarcinoma of unknown origin, highly suspicious of
adenocarcinoma, adenocarcinoma arising from ampulla
or bile duct and non-neoplastic diagnoses (Fig. 1). Pa-
tients under the age of 50 were grouped into the EOPC
cohort and were compared to older patients, referred to
here as the older PDAC group. Information extractedFig. 1 Search Results of London Royal Hospital archives from 18/09/2004 t
cPanIN: Pancreatic Intraepithelial Neoplasia; dIPMN: Intraductal Papillary Muc
Ductal Adenocarcinoma; gNS: unknown or not specified; hNETs: Neuroendo
etc); kSPN: Solid Pseudopapillary Neoplasm; lMCAC: Mucinous Cystadenocar
adenosquamous, signet ring cell carcinoma, mixed ductal-neuroendocri
Early Onset Pancreatic Cancerconsisted of the following: 1) Demographics: age, gender
and ethnicity. 2) Epidemiologic and genetic information:
history of alcohol excess, obesity (BMI > 30), previous
abdominal surgery or radiotherapy, allergy status, and
family history of pancreatic cancer or other related ma-
lignancies. Specific quantitative data on smoking history
in terms of duration, intensity, or recency were rarely
available thus smoking history was descriptive (never/ex/
current smoker) rather than in accordance with specific
definitions (e.g. pack-years). 3) Presenting symptoms:
Past medical history of chronic pancreatitis was consid-
ered positive if it was present more than 6 months be-
fore diagnosis, and recent onset diabetes mellitus was
defined as diabetes diagnosed within 3 years before diag-
nosis. 4) Clinical stage at diagnosis: record followed the
American Joint Committee on Cancer (AJCC) and the
Union for International Cancer Control (UICC) TNM
staging system 7th edition [35]. 5) Surgical management,
details of adjuvant and palliative treatment. 6) Survival
data. The date of diagnosis was defined as the date when
biopsy was taken. The date of last follow-up was used if
date of death was not available. The study was done
under Research Ethics approval (Reference Number: 05/
Q0408/65).
Statistical analysis
Differences between groups were calculated with
two-sided chi-square test (p < 0.05 was considered statis-
tically significant). The age was presented as a meano 18/09/2015. aCP: Chronic Pancreatitis, bAP: Autoimmune Pancreatitis;
inous Neoplasm; eMCN: Mucinous Cystic Neoplasm; fPDAC: Pancreatic
crine tumours (glucagonoma, large cell neuroendocrine carcinoma,
cinoma; mother: serous cystadenoma, undifferentiated carcinoma,
ne carcinoma, lymphomas (diffuse large B-cell lymphoma); nEOPC:
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dian value with 95% confidence intervals (CI). Survival
curves were estimated using the Kaplan–Meier method
and compared by the log-rank test. All statistical ana-
lyses were performed using IBM SPSS Statistics 24.0.
Results
Patient demographics, epidemiologic and genetic
characteristics
Our search identified 1275 cases; of 369 pancreatic can-
cer cases 35 were EOPC, comprising 9.5% of the total
PDAC population (Fig. 1). The general characteristics of
EOPC and older PDAC patients are presented in Table 1.
The mean age was 45.71 (33 to 50) years for the young
onset population while older PDAC patients had a mean
age of 66.19 (51 to 85) years. Gender distribution was
significantly different between EOPC and older PDAC
groups, with higher rate of male patients in the younger
cohort (71% vs 54%, p = 0.043). In terms of ethnicity, the
majority of older PDAC patients were British (70% vs
37% in EOPC cohort, p = 0.002), whereas the EOPC
group included a significant proportion of patients from
Asian and Central/Eastern European origin. There was
no significant difference in terms of modifiable and gen-
etic risk factors between the two groups. First-degree
family history in the EOPC cohort is presented in
Table 2. Only one of the 35 EOPC patients was affected
by a genetic syndrome (Lynch syndrome). Four EOPC
(11%) patients and 34 older PDAC patients (10%) had a
first-degree relative with history of any type of cancer
(p = 0.989). None of the EOPC and only 12 (4%) of the
older PDAC patients had a first-degree relative with pan-
creatic cancer (p = 0.25). Interestingly, one EOPC patient
had two 2nd degree relatives from parental side (an uncle
and a cousin) also diagnosed with pancreatic cancer at an
early age (50 and 49 years, respectively).
Symptoms at presentation
With regards to symptoms at presentation, obstructive
jaundice was the most frequent presenting symptom in
both groups, followed by anorexia, abdominal pain, nau-
sea and vomiting. Two EOPC (6%) patients presented
with early onset diabetes compared to 40 PDAC (12%)
patients (p = 0.299).
Pathology and clinical stage at diagnosis
A significantly lower number of EOPC patients (22.9%)
presented with localised resectable disease compared to
older PDAC patients (44%) (p = 0.015). A similar propor-
tion of EOPC (54%) and older PDAC (42%) patients had
locally advanced unresectable disease or presented with
distant metastases (23% vs 17%). In EOPC, half of the
patients with metastases at diagnosis had a single liver
metastasis and the other half had more than one site ofmetastasis. The most common sites of metastatic disease
were liver (75%), lung (37.5%), pleura and omentum
(12.5% each). Similarly, in older PDAC patients the most
common site of metastasis was liver, occurring alone in
just above half of the cases (53.5%) and in combination
with other sites in a further 15.5% of tumours. Other
single sites were lung (7%), peritoneum (7%), omentum
(1.7%) and pleura (1.7%). Tumour grading and AJCC/
UICC TNM stage of EOPC and older PDAC patients
did not differ, and there was no significant difference in
terms of the other pathological characteristics of tumours
(location, differentiation, stage, perineural invasion and
vascular invasion) between the two groups (Table 3).
Treatment and survival
All 8 (22.9%) EOPC and 147 (44%) PDAC patients with
localised disease underwent resection with curative in-
tent. The AJCC/UICC TNM stage of EOPC patients
who underwent resection was as follows: IA (n = 2), IIA
(n = 1), IIB (n = 5). Sixty per cent of EOPC patients re-
ceived adjuvant or palliative chemotherapy/radiotherapy
whereas only 46% of the older PDAC patients were fit
enough to receive the same treatment (p = 0.008) (Table 3).
Six (17.4%) EOPC and 77 (23%) PDAC patients re-
ceived a combination of chemotherapy/radiotherapy
and surgery with curative intent, out of which one
(16.7%) EOPC and six (7.8%) PDAC received this as
neoadjuvant treatment that down-staged their disease.
The median overall survival of the EOPC patients
(12 months, 5–18.9, 95% CI) was higher than in older
PDAC patients (9 months, 7.8–10.2, 95% CI) and
there was also a trend towards increased stage spe-
cific survival (25 vs to 13 months) but neither differ-
ence was statistically significant (Fig. 2 and Table 4).
Similarly, for patients with locally advanced disease,
the median overall survival was 11 months (3.9–18.1,
95%CI) for the EOPC patients and 8 months (6.5–9.4,
95%CI) for the older PDAC patients (p = 0.172). Re-
garding patients with metastatic disease, both cohorts
had a median survival of 6 months (p = 0.213) (Table 4).
Discussion
In this study, we performed a detailed retrospective ana-
lysis of EOPC patients with histologically confirmed
PDAC in the setting of one of the largest HPB centres in
the United Kingdom. While previous EOPC reports also
included patients with pathological “variants” (e.g. mu-
cinous cystic neoplasms) which are not included in the
current WHO classification of pancreatic ductal adeno-
carcinoma, our report is based on the most recent
PDAC classification and staging. We have used 50 years
as the cut-off age for EOPC patients, which, although ar-
bitrary, has been used previously [4–7]. A detailed sum-
mary of comparisons between different EOPC studies is
Table 1 EOPC and older PDAC demographics, past medical
history, environmental and genetic risk factors
Characteristics EOPC (35), %
(≤50 years)
PDAC (334), %
(> 50 years)
p value
Mean Age 45.71 66.19
(Range in years) (33 to 50) (51 to 85)
Gender 0.043
Male 25 (71%) 179 (54%)
Female 10 (29%) 155 (46%)
Ethnicity 0.002
British 13 (37%) 233 (70%)
Asian 5 (14%) 9 (3%)
Black 3 (9%) 22 (7%)
Other white background 4 (11%) 11 (3%)
Any other group 2 (6%) 12 (4%)
Missing 8 (23%) 47 (14%)
Smoking status 0.850
Current smoker 7 (20%) 55 (16%)
Ex-smoker 4 (11%) 45 (13%)
No 13 (37%) 109 (33%)
Missing 11 (31%) 125 (37%)
History of alcohol excess 0.556
Yes 9 (26%) 69 (21%)
No 14 (40%) 140 (42%)
Missing 12 (34%) 125 (37%)
Obesity 0.244
Yes 2 (6%) 23 (7%)
No 8 (23%) 37 (11%)
Missing 25 (71%) 274 (82%)
Genetic syndrome 0.989
Yes 1 (3%) 9 (3%)
No 30 (86%) 266 (80%)
Missing 4 (11%) 59 (18%)
History of chronic pancreatitis 0.092
Yes 5 (14%) 96 (29%)
No 23 (66%) 191 (57%)
Missing 7 (20%) 47 (14%)
History of diabetes 0.385
Yes 8 (23%) 58 (17%)
No 22 (63%) 233 (70%)
Missing 5 (14%) 43 (13%)
Allergya 0.853
Yes 2 (6%) 35 (10%)
No 15 (43%) 228 (68%)
Missing 18 (51%) 71 (21%)
Previous radiotherapy 0.838
Yes 1 (3%) 14 (4%)
Table 1 EOPC and older PDAC demographics, past medical
history, environmental and genetic risk factors (Continued)
Characteristics EOPC (35), %
(≤50 years)
PDAC (334), %
(> 50 years)
p value
No 23 (66%) 261 (78%)
Missing 11 (31%) 59 (18%)
Previous abdominal surgeryb 0.056
Yes 9 (26%) 78 (23%)
No 9 (26%) 194 (58%)
Missing 17 (49%) 62 (19%)
aAllergy to penicillin; bPrevious abdominal surgery included cholecystectomy,
lateral pancreaticojejunostomy
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PDAC groups were seen in demographic data. EOPC pa-
tients in our population were more frequently males, in
agreement with previous studies [5–7, 12, 13, 36, 37]. In
addition, our EOPC patients were less frequently of
white British background and more commonly Asian or
from ‘any other white background’. The latter comprised
mainly Central and Eastern Europeans. Similar findings
were reported by Raimondi et al. who demonstrated in a
worldwide study a higher number of male than female
patients and a peak in Central and Eastern European
countries followed very closely by Asian countries [28].
The association of gender and race/ethnic group with in-
cidence of pancreatic cancer has also been documented
in a US report conducted by the National Cancer Insti-
tute, where the authors showed the higher incidence and
mortality rate in men than in women in each racial/eth-
nic group, between the age of 30 and 54 [38]. Miller
et al., showed up to 50% higher incidence and mortality
rate in the black compared to the white population, for
the same age group (30–54 years) [38].
One of the putative explanations for the higher in-
cidence of EOPC in males is smoking, a known inde-
pendent risk factor for pancreatic cancer in all age
groups [3, 7, 28, 30, 39, 40]. Indirect association of
EOPC and smoking in males was first highlighted by
Raimondi et al. who correlated the higher EOPC
male/female ratio positively with an early onset ofTable 2 Family history of cancer in EOPC patients
EOPC patients Family history of cancer
1 Mother: endometrial cancer
2 Mother: colon and endometrial cancer,
mAunt: endometrial cancer, pGrandmother:
bowel cancer, pCousin: breast cancer (age 32),
Grandmother: stomach cancera
3 Father: esophageal cancer, Brother: colon cancer,
Sister: esophageal cancer
4 Sister: lung cancer (age 38)
p: paternal, m: maternal, aLynch syndrome
Table 3 EOPC and older PDAC tumour characteristics and
treatment details
Tumour Characteristics EOPC (N = 35), %
(≤50 years)
PDAC (N = 334), %
(> 50 years)
p value
Resectable 0.015
Yes 8 (22.9%) 147 (44%)
No 27 (77.1%) 186 (56%)
Missing 0 1 (0%)
Location 0.579
Head/Uncinate 27 (77%) 265 (79%)
Body/Tail 8 (23%) 62 (19%)
Missing 0 7 (2%)
Differentiation grade 0.315
Well 2 (6%) 15 (4%)
Moderate 16 (46%) 127 (38%)
Poor 12 (34%) 170 (51%)
Missing 5 (14%) 22 (7%)
Stages 0.194
I 2 (5.8%) 16 (5%)
II* 6 (17.1%) 117(34%)
III 19 (54.2%) 140 (42%)
IV 8 (22.9%) 57 (17%)
Missing 0 4 (1%)
Perineural invasion 0.348
Yes 12 (34%) 142 (43%)
No 23 (66%) 192 (57%)
Perivascular invasion
Yes 7 (20%) 122 (37%) 0.051
No 28 (80%) 212 (63%)
Chemotherapy/
radiotherapy
0.008
Yes 21 (60%) 153 (46%)
No 5 (14%) 131 (39%)
Missing 9 (26%) 50 (15%)
*Stage II p value = 0.032
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was provided by Piciucchi et al. [7], who, based on
patient interviews, demonstrated a significantly in-
creased risk of EOPC among the ‘current smokers’
group and a positive correlation with the ‘young age
at smoking initiation’ [7]. In our cohort, however,
only 31% of the total EOPC population had a smok-
ing history which was comparable to the older PDAC
cases (29%).
Interestingly, the highest incidence of EOPC patients
was reported in two independent studies conducted in
North Africa, in Morocco [36] and Egypt [41]: 17% of
PDAC patients were younger than 45 years in Morocco
[36], and almost 25% in the East Nile Delta were underthe age of 50 [41]. In both countries the male to female
ratio was around 2:1, in accordance with other reports.
Regarding smoking, in the Moroccan population only
12.5% of all EOPC patients were smokers [36]. In con-
trast, in Egypt smoking is highly prevalent (40% of the
general population are smokers). While the authors do
not report the smoking history of the EOPC patients,
they speculate that occupational and environmental ex-
posure to heavy metals like cadmium, nickel and chro-
mium, as well as other polluting chemicals, could
contribute to the high incidence of EOPC in this heavily
industrialised region [41]. Unfortunately, we do not have
any information on environmental exposure of our study
population, and the effect of pollution on our London-
based patients would be interesting to explore.
Our study did not identify any differences between
EOPC and older PDAC patients in any of the previously
identified risk factors for PDAC, i.e. alcohol intake, obes-
ity, history of chronic pancreatitis, history of diabetes,
previous abdominal surgery and previous radiotherapy.
The rate of recent onset diabetes was somewhat lower in
EOPC (6% EOPC vs 12% PDAC, p = 0.299) although this
was not statistically significant.
None of the patients in our EOPC cohort met the cri-
teria for a familial pancreatic cancer syndrome [42]. Four
of the EOPC patients in our cohort had a family history
of any cancer but none had a first-degree relative with
pancreatic cancer, and only one patient had a hereditary
genetic syndrome (Lynch Syndrome) associated with in-
creased risk of pancreatic cancer [22]. A similarly low in-
cidence of familial cases, with no significant difference
between young and old PDAC groups, has been reported
in other studies. In the cohort described by Duffy et al.
[10], only 2.2% of EOPC patients had a family history of
pancreatic cancer and no EOPC patients were affected
by any of the hereditary syndromes. Tingstedt et al. [5]
reported 3% of EOPC with a first-degree relative with
pancreatic cancer. However, somewhat higher incidences
were found by Piciucchi et al. [7] in both young and
older patients, where 8% and 6.3% of cases respectively
had a family history of pancreatic cancer. A recent study
by Ohmoto et al. [37] suggests a lack of association
between hereditary genetic factors and EOPC. The
authors assessed the mutation status of 49 genes in-
volved in hereditary syndromes in the germline of
EOPC patients younger than 40 years, but did not
find any variants [37]. In contrast, James et al. [17]
reported an overall incidence of familial pancreatic
cancer of 3%, with the percentage of patients
≤50 years of age being significantly higher than
among the sporadic cancer patients (36% and 18.3%,
respectively, p = 0.017). Overall, the underlying factors
influencing the young onset of pancreatic cancers re-
main to be determined.
Fig. 2 Kaplan Meier overall survival curve in EOPC and older PDAC patients. (y- axis: Cum Survival (cumulative survival), x-axis: time in months)
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jaundice, abdominal pain, and change in bowel habit,
nausea /vomiting, anorexia or weight loss) were largely
shared between the two cohorts, and both young and
old PDAC patients most commonly presented with ob-
structive jaundice, probably due to a high incidence of
lesions located in the pancreatic head. Interestingly, in a
study by Piciucchi et al. [7], jaundice at presentation oc-
curred in only 16% of the EOPC patients, a significantly
lower rate than in older PDAC patients (44%, p = 0.06)
[7]. This was probably due to a lower rate of tumours lo-
cated in the head of the pancreas (64% vs 83%, p = 0.03).
Jiang et al. [13] also reported a low frequency of jaundice
in EOPC patients, although this could not be explained
by tumour location.Table 4 Overall survival (in months) of EOPC and older PDAC
cohorts
Median survival (months)
EOPC (N = 35)
(≤50 years)
PDAC (N = 334)
(> 50 years)
p value
Entire cohorta 12 (5–18.9 95%CI) 9 (7.8–10.2 95%CI) 0.168
Stage I-II 25 (12.9–37 95%CI) 13(10.5–15.5 95%CI) 0.307
Stage III 11 (3.9–18.1 95%CI) 8 (6.5–9.4 95%CI) 0.172
Stage IV 6 (3.2–8.8 95%CI) 6 (4.8–7.2 95%CI) 0.213
aData missing for three EOPC and nine PDAC patientsThe two groups also showed similar pathological char-
acteristics. Poorly differentiated tumours tended to be
more common in older PDAC patients (34% vs 51%)
and moderately differentiated in EOPC (46% vs 38%),
but this was not statistically significant. Furthermore, no
difference was observed in the rates of perineural and
vascular invasion. Other studies have also showed that
the pathological features in EOPC patients are similar to
those seen in older PDAC patients, [8, 9] although the
presence of more histological variants, especially mucin-
ous carcinomas, has been observed in EOPC cases [8].
Interestingly, a lower rate of KRAS mutations in EOPC
patients was found in two studies, [9, 43], although both
were performed on a small number of cases (five and
seven, respectively).
In our data, EOPC patients presented at a more ad-
vanced stage compared to older PDAC group (77% vs
56%, p = 0.015) but they were more frequently fit for ad-
juvant or palliative treatment (60% vs 46%, p = 0.008).
While the overall survival of EOPC was similar to older
PDAC patients with no statistically significant difference,
EOPC patients who underwent surgical resection had a
longer median overall survival of 25 months compared
to 13 months for the same PDAC subpopulation. A
similar finding has been observed in previous studies,
with the highest survival of 41.8 months for resected
cases reported by Duffy et al. [10] which has been
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and being more suitable candidates for surgery and adju-
vant chemotherapy [10, 12, 13, 36, 37]. Furthermore, He
et al. also showed that EOPC patients had fewer
post-operative complications [12] and McWilliams et al.,
[14] attributed the better survival rate among young
people to a multitude of factors, including race, sex, year
of diagnosis, stage of disease, tumour location and treat-
ment [14].
Our study adds to a growing body of literature on the
demographic and clinicopathological characteristics of
EOPC patients, using contemporary classification and
staging manuals. There are some limitations to our
study: firstly, the disproportionate sample size of the two
comparison groups, EOPC and older PDAC, although
reflecting the general incidence of the disease and un-
avoidable, may have contributed to statistical errors in
our analysis. In addition, the retrospective nature of the
study has its own pitfalls, which include possible omis-
sion of patients that did not have a tissue diagnosis, and
review of medical records with sometimes incomplete
data. Finally, the study was conducted in a single tertiary
expert centre with referred cases and may over-
represent the patients that were suitable to undergo tis-
sue biopsy prior to receiving more aggressive treatment.
Enlarging the data set through a multi-centre collabora-
tive approach might produce more robust results.Conclusions
In conclusion, we present the data from a retrospective
study of histologically confirmed PDAC patients over an
11-year period establishing for the first time the demo-
graphic and clinicopathological characteristics of EOPC
in the multinational PDAC population inhabiting the
greater London area. Our results showed demographic
differences between EOPC and older PDAC patients,
but no difference in association with any currently
known risk factors for pancreatic cancer. EOPC patients
who undergo surgery have a significantly better survival
compared to their older counterparts, which reinforces
the value of this therapeutic option, in combination with
neoadjuvant chemotherapy/radiotherapy for downsta-
ging of the disease. As risk factors reported previously
and in our study do not point to any major differences
in demographic and clinicopathological characteristics
between EOPC and older PDAC patients, molecular in-
vestigations are warranted in order to understand the
molecular bases for the occurrence of this highly aggres-
sive malignancy in young populations.
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